Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Gabapentin in Elastic Liposomes: Preparation, Characterization, Drug Release, and Penetration Through Porcine Skin

Author(s):  Le Uyen Minh, Baltzley Sarah, AlGhananeem Abeer

Issue:  Nov/Dec 2018 - Volume 22, Number 6
View All Articles in Issue

Page(s):  498-503

Gabapentin in Elastic Liposomes: Preparation, Characterization, Drug Release, and Penetration Through Porcine Skin Page 1
Gabapentin in Elastic Liposomes: Preparation, Characterization, Drug Release, and Penetration Through Porcine Skin Page 2
Gabapentin in Elastic Liposomes: Preparation, Characterization, Drug Release, and Penetration Through Porcine Skin Page 3
Gabapentin in Elastic Liposomes: Preparation, Characterization, Drug Release, and Penetration Through Porcine Skin Page 4
Gabapentin in Elastic Liposomes: Preparation, Characterization, Drug Release, and Penetration Through Porcine Skin Page 5
Gabapentin in Elastic Liposomes: Preparation, Characterization, Drug Release, and Penetration Through Porcine Skin Page 6

Download in electronic PDF format for $75

Abstract:  In the outpatient pharmacy compounding, gabapentin, an anti-epileptic agent, has been commonly prescribed to be prepared alone or in combination with other agents in Pluronic lecithin organogel for transdermal pain management and palliative care. The objective of this study was to formulate and characterize gabapentin encapsulated elastic liposomes and then compare the gabapentin-based liposomes with compounded gabapentin-based Pluronic lecithin organogel regarding their efficiency in transdermal delivery of gabapentin. We demonstrated that our small 100-nm unilamellar vesicles of gabapentin encapsulated approximately 6.9 mg/mL Å} 0.2 mg/mL with up to 70% of encapsulation efficiency. Gabapentin released slowly from liposomes over 12 hours while it rapidly released from Pluronic lecithin organogel within 4 hours. We also showed that after 24 hours liposomes significantly accelerated the percutaneous penetration of gabapentin through the porcine skin leading to higher cumulative drug concentrations (~98% of drug permeated with a mean flux of 188.94 µg/cm2/h Å} 42.16 µg/cm2/h) as compared to Pluronic lecithin organogel (~55 % of drug permeated with a mean flux of 56.32 µg/cm2/h Å} 41.93 µg/cm2/h). In conclusion, the elastic liposomal formulation showed higher efficiency than the compounded Pluronic lecithin organogel in the transdermal delivery of gabapentin through porcine skin.

Related Keywords: gabapentin, anticonvulsant, epilepsy, transdermal administration, topical preparations, palliative care, liposomes, neuropathic pain, pain, formulation, elastic liposomes, liposomal preparations, dermal penetration, skin penetration, phospholipids

Related Categories: EXCIPIENTS, FORMULATIONS, PAIN MANAGEMENT, PEER-REVIEWED, NEUROLOGY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Gabapentin in Elastic Liposomes: Preparation, Characterization, Drug Release, and Penetration Through Porcine Skin
Le Uyen Minh
, Baltzley Sarah, AlGhananeem Abeer
Nov/Dec 2018
Pg. 498-503

Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Hong Eun Ji
, Sumanasekera Wasana, Le Uyen Minh
Jan/Feb 2022
Pg. 65-71

Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy?
Shakshuki Ayah
, Agu Remigius U
Nov/Dec 2019
Pg. 496-503

Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome
Brown Scott
, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
May/Jun 2010
Pg. 182-192

Topical Medications for Orofacial Neuropathic Pain
Bramwell Bethany L
May/Jun 2010
Pg. 200-203

Skin Penetration and Antinociception of Topical Gabapentin Formulations
Bryson Evan
, Asbill Scott, Sweitzer Sarah
Nov/Dec 2014
Pg. 504-511

Analgesic Efficacy and Transdermal Penetration of Topical Gabapentin Creams: Finding an Optimal Dose and Pre-treatment Time
Heustess Allie
, Spigener Shuler, Sweitzer Sarah, Romero-Sandoval Alfonso, Asbill Scott
Mar/Apr 2015
Pg. 167-173

Veterinary Transdermal Medications: A to Z
Davidson Gigi S
Mar/Apr 2003
Pg. 106-113

Effect of Penetration Enhancers on the Percutaneous Delivery of Pain Management Actives
Trimble John
, Light Bob
May/Jun 2016
Pg. 250-256

Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Beshay Sarah M
, Rivera Gerard, Balthasar Jan, Florea Naomi
Mar/Apr 2024
Pg. 111-116

Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Beshay Sarah M
, Rivera Gerard, Balthasar Jan, Florea Naomi
Jul/Aug 2015
Pg. 295-300

Compounded Drugs of Value in Outpatient Hospice and Palliative Care Practice
McNulty John P
, Muller George
May/Jun 2014
Pg. 190-200

Amitriptyline Hydrochloride 2%, Carbamazepine 2%, Gabapentin 10%, and Ketoprofen 2% Transdermal Gel
Allen Loyd V Jr
Mar/Apr 2024
Pg. 131

Amitriptyline Hydrochloride 2%, Carbamazepine 2%, Gabapentin 10%, and Ketoprofen 2% Transdermal Gel
Allen Loyd V Jr
Mar/Apr 2011
Pg. 157

Topical Treatment of Neuropathic Pain
Vadaurri Vince
May/Jun 2008
Pg. 182-190

Compounded Pain Formulations: What is the Evidence?
Asbill Scott
, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Mar/Apr 2024
Pg. 100-109

Compounded Pain Formulations: What is the Evidence?
Asbill Scott
, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Jul/Aug 2014
Pg. 278-286

In Vitro Permeability, Irritability, and Release Evaluation of Commonly Used Topical Diclofenac Gel Preparations (1%, 5%, and 10%)
Kohan Hamed Gilzad
, Baker David M, Sani Shabnam, Bielecki-Wilken Kathleen A, Ramirez Alfonso
Mar/Apr 2021
Pg. 146-155

Update on Managing Neuropathic Pain
McNulty Jack P
, Muller George
May/Jun 2009
Pg. 182-190

Clinical Nuggets and Pearls: Chronic Neuropathic Pain and Opioid Tolerance
Jones Marty
Jan/Feb 2002
Pg. 4-6

Return to Top